

Transparency
Declaration for
Payments by Chugai
Pharma Europe and
Chugai Pharma UK in
the UK & Ireland in
2017

Chugai Compliance



Chugai Pharma U.K. Ltd. and Chugai Pharma Europe Ltd. believe it is important to be transparent regarding interactions with Healthcare Professionals (HCPs), Other Relevant Decision Makers (ORDMs), Health Care Organisations (HCOs), national healthcare services (including the NHS) and with Patient Organisations.

- Payments made to HCPs/ORDMs and HCOs will be disclosed via central portals organised and managed by The Irish Pharmaceutical Healthcare Association (IPHA) and The Association of the British Pharmaceutical Industry (ABPI) for payments made in Ireland the UK respectively. These payments will be available for public scrutiny from July 1st 2016 and updated annually. Methodological notes will give support any to reader to better understand the manner in which Chugai manages such payments.
- Payments made to Patient Organisations will be disclosed via the company website. Details will be given as to the Patient Organisation, the nature of the engagement, the amount paid and a percentage this payment represents of the annual income of the patient organisation and updated annually. However, if the payment was for consultancy work undertaken by a HCP working on behalf of a Patient organisation then the payment will be disclosed twice (on the Chugai website as a payment to a Patient Organisation and on the ABPI or IPHA transparency portals as a payment to a HCP).
- Patients benefit from the collaboration between HCPs/ORDMs and the pharmaceutical industry through the development and appropriate use of innovative treatments that aim to improve patient care. HCPs/ORDMs and pharmaceutical companies regularly work together from early scientific research and clinical trial programmes to the use of medicines. As an integral part of the medicines development process it is entirely appropriate that fees are paid to HCPs/ORDMs to reimburse them for their time and expertise.
- The pharmaceutical industry is committed to ensuring the transparency of relationships with HCPs/ORDMs. Across Europe the industry has announced its intention to disclose payments to HCPs/ORDMs at an individual level by 2016 for payments made in 2015 onwards.
- The NHS and the pharmaceutical industry share a common goal in improving patient outcomes and this has been the foundation of Joint Working projects. The potential of such projects to deliver improvements that benefit patients has been proven in a range of services and therapies. Payments relating to Joint Working agreements will be disclosed via the company website and details will be given as to the NHS partner, the nature of the engagement and the amount paid. Such information is disclosed prior to the project starting and updated through the course of the project.

Here you can find information regarding:

1. [Support and interactions with Patient Groups](#)
2. [Joint Working arrangements](#)

The amount indicated represents payments made in the UK and Ireland for the whole of 2017. The data has been sourced from all Chugai businesses. The amounts indicated excludes money spent by our partners where we co-promote products. The amounts shown are inclusive of VAT and taxes where this is applicable.

Roche Products Limited and Chugai Pharma U.K. Ltd. have in place a co-promotion agreement for a Prescription Only Medicine (POM). To ensure both companies adhere with the ABPI requirements, each company will independently disclose payments associated with this co-promotion. Chugai Pharma U.K. Ltd. have distribution agreements with business partners based outside the UK. These business partners are responsible for the disclosure of any payments made by them.

For further information, please contact disclosure@chugai-pharm.co.uk.

1. Interactions with Patient Organisations:

Listed on this page you will find all financial interactions that Chugai Pharma U.K. Ltd. and Chugai Pharma Europe Ltd. has had with Patient Organisations during 2017. This includes financial donations to help with the service provided to patients, carers and family members. Chugai has made every effort to ensure the accuracy of this data.

Name of the Patient Organisation	Nature of interaction	Value of support
Myeloma UK	<p>Donation following reactive request of a donation of £10,000 to support core activities undertaken by Myeloma UK including patient and family information and support, Healthcare professional programmes, policy and public affairs</p> <p>The total funding given to this group represents less than 2% of its total earnings in 2017</p> <p>Myeloma UK Charity No. SC 026116</p> <p>https://www.myeloma.org.uk/</p>	£10,000
Myeloma UK	<p>For a member of staff to attend an advisory board meeting (not a registered Healthcare Professional)</p> <p>The total funding given to this group represents less than 1% of its total earnings in 2017</p> <p>Myeloma UK Charity No. SC 026116</p> <p>https://www.myeloma.org.uk/</p>	£800
Total		£10 800

2. Joint Working:

Joint Working describes situations where, for the benefit of patients, NHS and industry organisations pool skills, experience and/or resources for the joint development and implementation of patient-centred projects and share a commitment to successful delivery.

Chugai Pharma U.K. Ltd. will comply with Joint Working policies as defined by the ABPI and IPHA Codes of Practice in all discussions and arrangements.

Name of Joint Working Project	No joint working agreements were discussed or undertaken in 2017
--------------------------------------	--

For more information on the ABPI Code of Practice go to
<http://www.pmcpa.org.uk/thecode/Pages/default.aspx>

For more information on the IPHA Code of Practice go to
<http://www.ipha.ie/alist/publications.aspx?article=f8f9c1e9-344a-468c-b7d2-dc83530513b1>